These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32506280)

  • 1. Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system.
    Lee TY; Chen HY; Chen TY; Li SS; Fang WT; Wen YC; Lo YW; Ou HT
    Eur J Health Econ; 2020 Sep; 21(7):1105-1116. PubMed ID: 32506280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
    Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
    Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
    Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment.
    Marks DI; van Oostrum I; Mueller S; Welch V; Vandendries E; Loberiza FR; Böhme S; Su Y; Stelljes M; Kantarjian HM
    Cancer Med; 2019 Oct; 8(13):5959-5968. PubMed ID: 31436395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
    Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
    Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
    Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M
    Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
    Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Cox E; Wade R; Peron M; Dietz KC; Eastwood A; Palmer S; Griffin S
    Pharmacoeconomics; 2019 Sep; 37(9):1081-1091. PubMed ID: 30887470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Song J; Ma Q; Gao W; Cong Z; Xie J; Zimmerman Z; Belton L; Franklin J; Palmer S
    Adv Ther; 2019 Apr; 36(4):950-961. PubMed ID: 30758745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
    Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.
    Stelljes M; Advani AS; DeAngelo DJ; Wang T; Neuhof A; Vandendries E; Kantarjian H; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e836-e843. PubMed ID: 35643855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
    Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
    DeAngelo DJ; Advani AS; Marks DI; Stelljes M; Liedtke M; Stock W; Gökbuget N; Jabbour E; Merchant A; Wang T; Vandendries E; Neuhof A; Kantarjian H; O'Brien S
    Blood Cancer J; 2020 Aug; 10(8):81. PubMed ID: 32769965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions.
    Short NJ; Jabbour E; Jain N; Kantarjian H
    J Hematol Oncol; 2024 May; 17(1):32. PubMed ID: 38734670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
    Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
    Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
    Kantarjian HM; Su Y; Jabbour EJ; Bhattacharyya H; Yan E; Cappelleri JC; Marks DI
    Cancer; 2018 May; 124(10):2151-2160. PubMed ID: 29508899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
    Brivio E; Locatelli F; Lopez-Yurda M; Malone A; Díaz-de-Heredia C; Bielorai B; Rossig C; van der Velden VHJ; Ammerlaan ACJ; Thano A; van der Sluis IM; den Boer ML; Chen Y; Sleight B; Brethon B; Nysom K; Sramkova L; Øra I; Vinti L; Chen-Santel C; Zwaan CM
    Blood; 2021 Mar; 137(12):1582-1590. PubMed ID: 33067614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
    Cassaday RD; Marks DI; DeAngelo DJ; Jabbour EJ; Advani AS; O'Brien S; Wang T; Neuhof A; Vandendries E; Kantarjian HM; Stock W; Stelljes M
    Br J Haematol; 2020 Nov; 191(3):e77-e81. PubMed ID: 32805058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.